WX-554 / Heidelberg Pharma - LARVOL DELTA

MEK 1/2 inhibitors in the treatment of gynecologic malignancies (Gynecol Oncol) - “This paper reviews the translational evidence in favor of MEK inhibitors in cancer, their role in gynecologic malignancies, and details regarding the status of the fourteen MEK inhibitors currently being clinically tested: trametinib, selumetinib, pimasertib, refametinib, PD-0325901, MEK162, TAK733, RO5126766, WX-554, RO4987655, cobimetinib, AZD8330, MSC2015103B, and ARRY-300.” 

Review • Oncology

Wilex: Q1 2014 Results (Wilex) - "Starting in April 2012, a phase Ib/II dose escalation trial with WX-554 was conducted with cancer patients in the United Kingdom. This open-label trial investigated the safety, pharmacokinetics, pharmacodynamics and clinical activity of WX-554 in patients with solid tumours. Due to the discontinuation of development activities at WILEX AG, this trial was terminated in accordance with good clinical practice and the authorities were notified of this at the beginning of April"

Trial termination • Oncology

The Therapeutic Potential of MEK1/2 inhibitors in the treatment of gynecological cancers: Rational Strategies and Recent Progress. (PubMed, Curr Cancer Drug Targets) - "MEK1/2 inhibitors demonstrate promising efficacy and anticancer activity to treat this malignancy and captured much attention in the past decade. Here, we summarized the role of MAPK/MEK/ERK pathway in the pathogenesis of gynecological cancer, with particular emphasis on MEK inhibitors in clinical settings including PD-0325901, Selumetinib, Cobimetinib, Refametinib, Trametinib, Pimasertib, MEK162 and WX-554 in gynecologic cancers."

Journal • Gynecologic Cancers • Oncology • Solid Tumor